Details

Discovery of novel isoxazole-based small-molecule Toll-like receptor 8 antagonists
ID Matziol, Troy (Author), ID Talagayev, Valerij (Author), ID Slokan, Tjaša (Author), ID Strašek Benedik, Nika (Author), ID Holze, Janine (Author), ID Sova, Matej (Author), ID Wolber, Gerhard (Author), ID Weindl, Günther (Author)

.pdfPDF - Presentation file, Download (7,65 MB)
MD5: C935DC4824C87127DEAA221A89B140C5
URLURL - Source URL, Visit https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c03148 This link opens in a new window

Abstract
Toll-like receptor 8 (TLR8) recognizes viral and bacterial RNA, initiating inflammatory responses that are crucial for innate immunity. Dysregulated TLR8 signaling contributes to autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis, driving chronic inflammation and tissue damage. Therefore, targeting TLR8 has gained attention as a promising therapeutic strategy. We report a novel selective TLR8 antagonist scaffold identified through computational modeling and simulation. In silico-guided rational drug design and synthesis led to potent isoxazole-based compounds that were characterized by structure–activity relationships. The most active compounds inhibited TLR8-mediated signaling in cell lines and primary cells, reduced MyD88 recruitment, suppressed NF-κB- and IRF-dependent signaling, and decreased inflammatory responses. In silico and pharmacological analyses demonstrated competitive binding to the pocket of chemical ligands within the TLR8 dimerization interface. These highly selective and potent TLR8 antagonists possess favorable physicochemical properties, representing potential clinical candidates for TLR8-targeted therapy.

Language:English
Keywords:antagonists, genetics, peptides, proteins, receptors, screening assays
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:Str. 4888-4907
Numbering:Vol. 68, iss. 4
PID:20.500.12556/RUL-176588 This link opens in a new window
UDC:615.2-021.321
ISSN on article:1520-4804
DOI:10.1021/acs.jmedchem.4c03148 This link opens in a new window
COBISS.SI-ID:235973123 This link opens in a new window
Publication date in RUL:04.12.2025
Views:484
Downloads:253
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of medicinal chemistry
Shortened title:J. med. chem.
Publisher:American Chemical Society
ISSN:1520-4804
COBISS.SI-ID:512806681 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:Tollu podoben receptor 8, antagonisti TLR8, izoksazol, imunost, tarčna zdravila

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J1-4417
Name:Razvoj novih nizkomolekularnih modulatorjev Tollu podobnih receptorjev 7 in 8 za imunoterapijo raka

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:BI-DE/23-24-011
Name:Računalniško podprto načrtovanje, sinteza in biološko vrednotenje modulatorjev Tollu podobnega receptorja 8

Funder:ARIS - Slovenian Research and Innovation Agency
Funding programme:Young researchers

Funder:German Research Foundation
Project number:RA 895/16-1

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back